IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified 83-amino acid analogue of IGF-1 with an N-terminal arginine extension and Glu3→Arg3 substitution, conferring a half-life of approximately 20–30 hours versus 12–15 minutes for native IGF-1.
Recovery archive
Published recovery field note
IGF-1 LR3: Dosage, Benefits, FDA Status & Clinics (2026)
IGF-1 LR3 FDA status: Not FDA-approved. IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified 83-amino acid analogue of IGF-1 with an N-terminal
Context first
Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.
Connected topics